Open AccessXRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: A meta‐analysis
Author(s) -
Sun Haiming,
Qiao Yuandong,
Zhang Xuelong,
Xu Lidan,
Jia Xueyuan,
Sun Donglin,
Shen Chao,
Liu An,
Zhao Yanling,
Jin Yan,
Yu Yang,
Bai Jing,
Fu Songbin
Publication year - 2010
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01608.x
Subject(s) - xrcc3 , bladder cancer , odds ratio , lung cancer , meta analysis , confidence interval , medicine , oncology , lung cancer susceptibility , population , cancer , biology , genotype , genetics , single nucleotide polymorphism , gene , environmental health
Several studies have investigated the associations between X‐ray repair cross‐complementing group 3 ( XRCC3 ) Thr241Met polymorphism and the susceptibility to lung cancer and bladder cancer, but results have been inconclusive. In order to derive a more precise estimation of the relationship, a meta‐analysis was performed. A total of 22 case control studies, including 2976 cases and 4495 controls for lung cancer, and 3445 cases and 4599 controls for bladder cancer, met the inclusion criteria and were selected. Overall, there was no evidence showing a significant association between XRCC3 Thr241Met polymorphism and lung cancer risk. Furthermore, the results for bladder cancer showed that significant decreased risk was found for the additive model (odds ratio [OR] = 0.959, 95% confidence interval [CI], 0.924–0.996) and dominant model (OR = 0.982, 95% CI, 0.963–1.000) but not for the recessive model (OR = 0.958, 95% CI, 0.905–1.014). In summary, our meta‐analysis indicates that XRCC3 Thr241Met polymorphism may be weakly associated with the risk of bladder cancer. ( Cancer Sci 2010)